News
Good news for sleep in patients with axial spondyloarthritis – ixekizumab effectively reduces night-time back pain
The targeted treatment of axial spondyloarthritis currently relies on the anti-inflammatory effects of tumor necrosis factor (TNF) inhibitors, interleukin IL-17 inhibitors, and Janus kinase (JAK) inhibitors. Besides the objective efficacy of these targeted treatments, it is crucial to describe their influence on subjective symptoms for decision-making in clinical practice. The evaluation of the analgesic effect of ixekizumab (IXE) was provided by the randomized controlled trial COAST-V.
Two Current Perspectives on the Importance of (Par)enteral Nutrition in Cancer Patients
Adequate (par)enteral nutrition is crucial for cancer patients in terms of prognosis and quality of…
To what extent can improvement of nutritional status through parenteral nutrition affect the results of oncological treatment?
Just like cancer patients and their caregivers, doctors often overlook the risk of malnutrition.…
Does SGLT2 Inhibitor Administration Benefit Diabetics with Low Cardiorenal Risk?
There is growing evidence of the cardiorenal protective effects of sodium-glucose cotransporter 2…
6 Possible Benefits of Adding Empagliflozin to Metformin
Currently, there is intense discussion about the advantages of sodium-glucose co-transporter 2…
The Importance of Proper Protein and Calorie Intake in Critically Ill Patients – Insights from Recent Comparisons
The issue of nutrition, especially proteins, is a crucial aspect affecting the overall health and…
Impact of Early Administration of High Protein Dose on Mortality of Critically Ill Patients
Energy intake and the composition of individual macronutrients in patients in intensive care units…
MDT Board: a unique project for doctors caring for patients with lung diseases and other thoracic pathologies
A unique concept of a cooperative thoracic group has been created in the Czech Republic, involving…
Population Pharmacokinetic Model in Patients with von Willebrand Disease
Dutch authors presented a potential population pharmacokinetic model describing levels of von…
Pharmacokinetics of Concentrates for the Treatment of von Willebrand’s Disease
Von Willebrand's disease (vWD) is characterized by a deficiency or reduced functional capacity of…